2022 World Conference on Lung Cancer (ePosters)-EP08.01-024. Multicenter Real Life Clinical Outcomes of PDL-1 Tested Patients with Non Small Cell Lung Cancer (NSCLC) in Turkey

EP08.01-024. Multicenter Real Life Clinical Outcomes of PDL-1 Tested Patients with Non Small Cell Lung Cancer (NSCLC) in Turkey

Back to course

Pdf Summary

This study aimed to evaluate the real-life clinical outcomes of non-small cell lung cancer (NSCLC) patients who underwent PD-L1 testing in Turkey. The data of 338 NSCLC patients from January 2010 to January 2020 were retrospectively evaluated from eight different centers across Turkey. The majority of patients included in the study were male (79.6%) with a mean age of 63. Smoking status of the patients was 39.3% active smokers, 43.5% ex-smokers, and 14.2% nonsmokers. The most common histopathology was adenocarcinoma (65.7%), followed by squamous cell carcinoma (20.7%). PD-L1 testing was performed on primary tumors, metastatic regions, and pleural effusion.<br /><br />The median progression-free survival (PFS) of the patients was 7 months, and the median overall survival (OS) was 13 months. The most common sites of metastasis were the brain, liver, adrenal gland, contrary lung, distant lymph nodes, and pleural metastasis. Driver mutations were detected in 9.8% of patients (EGFR), 3% (ALK fusion), 0.6% (ROS-1 fusion), and 0.6% (BRAF). About 49.4% of patients had a PD-L1 expression level of 1%, while 25.4% had a PD-L1 level of 50% and 13.6% had a PD-L1 level of 80%.<br /><br />There was no significant difference in PFS and OS between PD-L1 positive and negative groups. Similarly, there was no significant difference in PFS and OS between patients with PD-L1 levels of 50% or higher compared to those with levels below 50%. The most common first-line treatment was platinum combination chemotherapy, followed by single-agent chemotherapy, tyrosine kinase inhibitors, chemotherapy-immunotherapy combination, and immunotherapy. In the second-line therapy, most patients received chemotherapy, followed by tyrosine kinase inhibitors and immunotherapy.<br /><br />The median OS in patients who received immunotherapy as first or second-line therapy was 17 months compared to 13 months in the non-immunotherapy group, although this difference was not statistically significant. The study concludes that immunotherapy should be an essential part of NSCLC treatment in underdeveloped and developing countries based on the real-life median OS of 17 months in patients who received immunotherapy.

Asset Subtitle

Ozan Yazici

Meta Tag

Speaker Ozan Yazici

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

non-small cell lung cancer

NSCLC

PD-L1 testing

Turkey

clinical outcomes

metastasis

driver mutations

progression-free survival

overall survival

immunotherapy